Head and Neck Cancer - New Insights into a Heterogeneous Disease

J. Klussmann

DOI: https://doi.org/10.1159/000477255

2017-05-17

Oncology Research and Treatment

Abstract:Despite improvements in diagnosis and therapy, morbidity and mortality have remained high and appropriate treatment of patients still is a major challenge. Most cases are diagnosed with locally advanced disease, and multimodal treatment consists of concomitant chemoradiotherapy or surgery followed by riskadapted radio(chemo)therapy. Although it is conceivable that distinct patient subgroups might benefit from treatment de-escalation (e.g., HPV-related HNSCC) or targeted therapy, effective personalized treatment options are not yet in clinical use for HNSCC. The aim of this issue of Oncology Research and Treatment is to highlight new insights into the biology of HNSCC, to discuss their possible implications for established treatment modalities, to point to future therapeutic developments, and to call attention to open questions which should be addressed by clinical trials. Jou and Hess [3] focused on recent data derived from integrative genomics analysis and multi-scale modeling approaches regarding the biological and clinical diversity of HNSCC. Wagner et al. [4] gave an overview of the newly recognized tumor entity ‘HPV-related HNSCC’. Semrau [5] discussed modern treatment technologies and new developments of radiation oncology. In their original article, Wuerdemann et al. [6] compared the outcome of patient cohorts with HPV-related and -unrelated oropharyngeal cancers treated with primary surgery. Schuler at al. [7] outlined novel treatment options for HNSCC, especially in the field of immunotherapy.